{
    "clinical_study": {
        "@rank": "99160", 
        "arm_group": {
            "arm_group_label": "Group 1", 
            "description": "Patients treated with Regorafenib under practical manner for gastrointestinal stromal tumors progressed after cancer chemotherapy."
        }, 
        "brief_summary": {
            "textblock": "The objective of this study is to assess safety and effectiveness of Regorafenib using in\n      real clinical practice."
        }, 
        "brief_title": "Regorafenib Post-marketing Surveillance in Japan", 
        "completion_date": {
            "#text": "August 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Gastrointestinal Stromal Tumors", 
        "condition_browse": {
            "mesh_term": "Gastrointestinal Stromal Tumors"
        }, 
        "detailed_description": {
            "textblock": "This study is a regulatory post-marketing surveillance in Japan, and it is a local\n      prospective and observational study of patients who have received Regorafenib for\n      gastrointestinal stromal tumors progressed after cancer chemotherapy.\n\n      A total of 135 patients are to be enrolled and assessed in 6 months standard observational\n      period. At 12 months and 24 months after the first administration of Regorafenib for\n      confirmation of efficacy information including treatment duration and survival status of the\n      patient."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients who are treated with Regorafenib/ STIVARGA and meet the product label\n\n        Exclusion Criteria:\n\n          -  Patients who are treated with Regorafenib/ STIVARGA and don't meet the product label"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Patients who are treated with Regorafenib/STIVARGA and meet the product label"
            }
        }, 
        "enrollment": {
            "#text": "135", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 29, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01933958", 
            "org_study_id": "16732", 
            "secondary_id": "STIVARGA-GIST-01"
        }, 
        "intervention": {
            "arm_group_label": "Group 1", 
            "description": "The usual dosage is 160 mg of Regorafenib/ STIVARGA taken orally after meal once daily for 3 weeks on therapy followed by 1 week off therapy to comprise a cycle of 4 weeks.", 
            "intervention_name": "Regorafenib (Stivarga, BAY73-4506)", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Regorafenib", 
            "Gastrointestinal stromal tumors"
        ], 
        "lastchanged_date": "May 7, 2014", 
        "link": [
            {
                "description": "Click here and search for drug information provided by the FDA.", 
                "url": "http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm"
            }, 
            {
                "description": "Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.", 
                "url": "http://www.fda.gov/medwatch/safety.htm"
            }
        ], 
        "location": {
            "facility": {
                "address": {
                    "city": "Many Locations", 
                    "country": "Japan"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_groups": "1", 
        "official_title": "Drug Use Investigation of Regorafenib/ STIVARGA for Gastrointestinal Stromal Tumor Progressed After Cancer Chemotherapy", 
        "overall_contact": {
            "email": "clinical-trials-contact@bayerhealthcare.com", 
            "last_name": "Bayer Clinical Trials Contact"
        }, 
        "overall_official": {
            "affiliation": "Bayer", 
            "last_name": "Bayer Study Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Ministry of Health, Labor and Welfare", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "August 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Number of patients with adverse drug reactions (ADRs) from the first administration of regorafenib.", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 6 months"
            }, 
            {
                "measure": "Number of patients with serious adverse events(SAEs)  from the first administration of regorafenib.", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 6 months"
            }, 
            {
                "measure": "Number of Patients with serious adverse drug reactions (SADRs) from the first administration of Regorafenib", 
                "safety_issue": "Yes", 
                "time_frame": "up to 6 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01933958"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "overall survival (OS)", 
                "safety_issue": "No", 
                "time_frame": "Up to 3 years"
            }, 
            {
                "description": "TTF is defined as the time interval from start of Regorafenib/ STIVARGA therapy to the date of permanent discontinuation for any reason including disease progression, adverse event, patient preference or death.", 
                "measure": "time to treatment failure (TTF)", 
                "safety_issue": "No", 
                "time_frame": "Up to 3 years"
            }, 
            {
                "measure": "tumour response", 
                "safety_issue": "No", 
                "time_frame": "Up to 3 years"
            }, 
            {
                "description": "Integration analysis    including incidence and risk factor of adverse drug reaction (ADR), serious adverse event (SAE) and serious adverse drug reaction (SADR)", 
                "measure": "Integration analysis for safety in drug use investigations (DUIs) for both colorectal cancer and gastrointestinal stromal tumor.", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 3 years"
            }
        ], 
        "source": "Bayer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bayer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}